Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Patient Derived Xenograft (PDX) Models Market Size From 2025 to 2034?
The market for patient derived xenograft (pdx) models has experienced swift expansion in recent times. It is projected to increase from $0.4 billion in 2024 to $0.47 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. This robust growth during the historical period can be accredited to various factors such as investment in research and development, regulatory backing, partnerships, collaborations, a rising number of contract research organizations (CROs), and an increasing prevalence of cancer cases.
In the coming years, the market size of patient derived xenograft (pdx) models is anticipated to experience exponential growth, reaching$0.81 billion in 2029 with a compound annual growth rate (CAGR) of 14.9%. This growth within the forecast period can be credited to factors such as the need for personalised medicine, a surge in demand for humanized PDX models, increasing cancer prevalence, emphasis on precision oncology, and heightened investment in R&D for cancer research. Throughout the forecast period, the market will see major trends including technological advancements, a soaring demand for humanized PDX models, joint research efforts, amplified investment in cancer research, and a heightened focus on immuno-oncology.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
What External and Internal Drivers Are Contributing to the Growth of thePatient Derived Xenograft (PDX) Models Market?
The growth of the patient-derived xenograft (PDX) models market is anticipated to be fueled by the rising demand for personalized medicine. Personalized medicine customizes medical care to match the specific attributes of each patient, taking into account genetics, environment, and lifestyle. As genomic research progresses, enabling treatments to be customized based on individual genetic profiles, the demand for personalized medicine is growing. This leads to more precise and effective healthcare outcomes. PDX models support personalized medicine by facilitating the testing of patient-specific tumors to anticipate treatment responses and adjust therapies accordingly. For example, the Personalized Medicine Coalition (PMC), an American nonprofit umbrella organization, reported in February 2024 that the FDA sanctioned 16 new personalized treatments for rare diseases in 2023, a substantial upsurge from six approvals in 2022. As a result, the patient-derived xenograft (PDX) models market growth is driven by the demand for personalized medicine.
What Segment Types Define the Patient Derived Xenograft (PDX) Models Market Structure?
The patient derived xenograft (pdx) modelsmarket covered in this report is segmented –
1) By Type: Mice Models; Rat Models
2) By Technique: Heterotopic Implantation; Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Patient Derived Xenograft (PDX) Models Market?
North America was the largest region in the patient derived xenograft (PDX) models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Patient Derived Xenograft (PDX) Models Market?
In the patient-derived xenograft (PDX) models market, major players are employing innovative tactics such as developing models with in vivo bioluminescence imaging capabilities which allow real-time tracking of tumor development. This advanced imaging technique enhances the PDX models by offering non-invasive real-time surveillance of tumor metastasis and responses to treatment, thereby increasing the effectiveness of drug development’s preclinical research. In March 2024, for example, India’s InVitro Research Solutions Private Limited, a Contract Research Organization (CRO), introduced a cutting-edge orthotopic model of human glioblastoma in NSG-SGM3 mice, employing PDX and in vivo bioluminescence imaging. This model is intended to provide personalized treatment for glioblastoma, notably the most widespread and aggressive brain cancer. Such models are pivotal for understanding glioblastoma biology and testing new target therapies and immunotherapies to enhance patient outcomes.
View the full report here:
What Is the Definition of the Patient Derived Xenograft (PDX) Models Market?
Patient-derived xenograft (PDX) models involve transplanting human tumor tissue into immunodeficient animal hosts. They mimic the complexity of human tumors more closely than traditional cell line models. PDX models are crucial for studying tumor biology and testing potential cancer therapies before clinical trials.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17226
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model